Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 10 mg/mL)
Drug ClassSelectin blockers
Ongoing and
Completed Studies


  • Indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Crizanlizumab-tmca (Adakveo) functions as a P-selectin inhibitor, aiming to reduce microvascular vaso-occlusions common in sickle cell disease. Its effectiveness was demonstrated in the SUSTAIN study by significantly reducing the incidence of vasoocclusive crises and prolonging the time to the first and second occurrence.
  • Four systematic reviews/meta-analyses focused on Adakveo's effectiveness in treating sickle cell disease and its associated complications.
  • Compared to other treatment options such as hydroxyurea and L-glutamine, Adakveo presents an alternative targeting the reduction of vasoocclusive crisis frequency. When combined with voxelotor, an antagonistic effect was observed, while its combination with L-glutamine indicated either potential synergy or a non-detrimental effect, suggesting usefulness in combined therapies.
  • The safety profile of crizanlizumab-tmca is similar to that of a placebo, with no significant differences in adverse or serious adverse events reported. This highlights its potential as a viable option for patients, including those with previous treatment attempts or specific sickle cell disease genotypes.
  • The benefits of using Adakveo appear to be consistent across various patient subgroups, irrespective of concurrent hydroxyurea use, history of VOC frequency, or genotype. This suggests wide applicability in the treatment of sickle cell disease. Preliminary evidence also supports its efficacy and safety in older adolescent and adult patients aged 16 years and older, indicating a targeted demographic for its application.
  • Notwithstanding the positive outcomes, more comprehensive clinical trials are necessary, particularly among pediatric populations younger than 16 years and in scenarios involving combination therapy, to fully understand the role of crizanlizumab-tmca in the management of sickle cell disease.